Protocol List

The Protocol List provides a listing of NCI clinical trials that are supported by the CTSU for which protocol documents are maintained on the CTSU members’ website. The trials on the list are either active, near activation, or temporarily closed. The list may be sorted by any topic in the header row (e.g., Protocol Number, Lead Organization, NIH Program, Status, or Phase) by clicking on a column header; click a second time to reverse the sort. The protocol list can be exported to an Excel or CSV file, or printed by selecting the arrow icon located above the header row.

*Some accruals have occurred outside of the CTSU systems and are collected manually, thus the total accrual number may not be accurate.
#Protocol NumberLead OrganizationNIH ProgramDiseaseStatusProtocol TitlePhaseActual/Planned Intervention AccrualScreening AccrualStep Type(s)
  • First Page
  • Previous Page
  • Page 1 of 6
  • Next Page
  • Last Page
  • Last update: 2:14:59 PM UTC
110014LAO-11030ETCTNHematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Miscellaneous and Metastatic CancerActiveA Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor MalignanciesPilot20/40N/AINTERVENTION
210020LAO-CT018ETCTNBreast CancerActiveA Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast CancerII64/90N/AINTERVENTION
310066LAO-CT018ETCTNGastrointestinal CancerActiveA Phase 1/2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)I/II38/49N/AINTERVENTION
410150LAO-11030ETCTNFemale Reproductive System CancerActiveA Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian CancerI/II27/96N/AINTERVENTION
510200LAO-MD017ETCTNLeukemiaActiveA Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid LeukemiaI/II1/48N/AINTERVENTION
610216LAO-OH007ETCTNLung, Mediastinal, and Pleural CancerActiveA Phase I/II Study of AZD9291(Osimertinib) and CB-839 HCl in Patients with EGFR Mutant Non-Small Cell Lung CancerI/II1/18N/AINTERVENTION
710302LAO-NJ066ETCTNBreast CancerActivePhase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast CancerII0/70N/AINTERVENTION
89979LAO-MN026ETCTNMiscellaneous and Metastatic CancerActivePhase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain MetastasesI8/47N/AINTERVENTION
9A031102ALLIANCENCTNCNS Cancer (Primary tumor);Germ Cell CancerActiveA Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell TumorsIII272/420N/AINTERVENTION
10A031704ALLIANCENCTNKidney CancerActivePD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]III122/1046N/AINTERVENTION
11A211601ALLIANCENCORPBreast CancerActiveEvaluation of Mammographic Breast Density Effect of Aspirin: A Companion to Alliance Study A011502IIIN/AN/AOTHER
12A211701ALLIANCENCORPN/AActiveA Prospective Study to Establish a New Onset Hyperglycemia and Diabetes (NOD) CohortIIIN/AN/AOTHER
13EA6141ECOG-ACRINNCTNSkin CancerTemporarily Closed to AccrualRandomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV MelanomaII/III250/400N/AINTERVENTION
14EA6174ECOG-ACRINNCTNSkin CancerActiveSTAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III TrialIII47/500N/AINTERVENTION
15EA8143ECOG-ACRINNCTNKidney CancerActiveA Phase 3 RandOmized Study Comparing PERioperative Nivolumab Vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)III450/766506SCREENING,INTERVENTION
16EA8171ECOG-ACRINNCTNMale Reproductive System CancerActiveMultiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate CancerII156/852N/AINTERVENTION
17EA9131ECOG-ACRINNCORPLeukemiaActiveA Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)II148/200N/AINTERVENTION
18EAI142ECOG-ACRINNCTNBreast CancerActive[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast CancerII70/99N/AINTERVENTION
19NRG-BR002NRGNCTNMiscellaneous and Metastatic CancerTemporarily Closed to AccrualA Phase IIR/III Trial of Standard of Care Therapy with or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast CancerII/III129/360N/AINTERVENTION
20NSABP-B-51NRGNCTNBreast CancerActiveA Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant ChemotherapyIII1480/1636N/AINTERVENTION
21RTOG-1112NRGNCTNGastrointestinal CancerActiveRandomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular CarcinomaIII188/368N/AINTERVENTION
22S1512SWOGNCTNSkin CancerActiveA Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)II36/56N/AINTERVENTION
23S1826SWOGNCTNLymphomaActiveA Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin LymphomaIII85/987N/AINTERVENTION
2410057LAO-NJ066ETCTNFemale Reproductive System Cancer;Lymphoma;Skin CancerTemporarily Closed to AccrualA Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin TumorsII38/68N/AINTERVENTION
2510061LAO-PA015ETCTNMiscellaneous and Metastatic CancerActiveA Phase 1 Study of MK-3475 (Pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid TumorsI14/36N/AINTERVENTION
2610070LAO-MD017ETCTNLung, Mediastinal, and Pleural Cancer;Miscellaneous and Metastatic CancerTemporarily Closed to AccrualPhase 1/2 Study of Navitoclax Plus Vistusertib in Patients with Relapsed Small Cell Lung Cancer (SCLC) and Other Solid TumorsI/II14/24N/AINTERVENTION
2710096LAO-CT018ETCTNMale Reproductive System CancerActiveA Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE)I/II8/18N/AINTERVENTION
2810145LAO-NCIETCTNLymphoma;Miscellaneous and Metastatic CancerActivePhase Ib Combination Study of Copanlisib and Nivolumab in Advanced Solid Tumors and LymphomasI25/41N/AINTERVENTION
2910146LAO-NC010ETCTNBreast CancerTemporarily Closed to AccrualRandomized Phase 2 Clinical Trial of Nab-Paclitaxel + MEDI4736 (Durvalumab) + Neoantigen Vaccine Vs. Nab-Paclitaxel + MEDI4736 (Durvalumab) in Patients with Metastatic Triple Negative Breast CancerII0/70N/AINTERVENTION
3010166LAO-MD017ETCTNLung, Mediastinal, and Pleural CancerActiveA Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung CancerII8/24N/AINTERVENTION
3110170LAO-CT018ETCTNKidney Cancer;Miscellaneous and Metastatic CancerActiveA Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor MalignanciesII11/60N/AINTERVENTION
3210193LAO-MN026ETCTNLymphomaActivePhase 2 Study of Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell LymphomaII1/106N/AINTERVENTION
3310217LAO-TX035ETCTNMiscellaneous and Metastatic CancerActiveA Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients with Advanced Solid TumorsI6/102N/AINTERVENTION
3410220LAO-TX035ETCTNCNS Cancer (Primary tumor);Lung, Mediastinal, and Pleural Cancer;Miscellaneous and Metastatic Cancer;Soft Tissue Cancer/SarcomaActiveA Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant TumorsII3/108N/AINTERVENTION
359948LAO-MN026ETCTNFemale Reproductive System CancerActivePhase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine with or without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube CancerI19/24N/AINTERVENTION
36A021502ALLIANCENCTNGastrointestinal CancerActiveRandomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch RepairIII289/700N/AINTERVENTION
37A021703ALLIANCENCTNGastrointestinal CancerActiveRandomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)III30/402N/AINTERVENTION
38A041501ALLIANCENCTNLeukemiaActiveA Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALLIII103/324N/AINTERVENTION
39A051701ALLIANCENCTNLymphomaActiveRandomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing LymphomasII/III38/367N/AINTERVENTION
40A071401ALLIANCENCTNCNS Cancer (Primary tumor)Temporarily Closed to AccrualPhase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 MutationsII40/124322SCREENING,INTERVENTION
41A151804ALLIANCENCTNMiscellaneous and Metastatic CancerActiveEstablishment of a National Biorepository to Advance Studies of Immune-Related Adverse EventsOther1/240N/AINTERVENTION
42A221505ALLIANCENCORPBreast CancerActiveRT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast ReconstructionIII487/880N/AINTERVENTION
43AREN1721COGNCTNKidney CancerActiveA Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age GroupsII7/70N/AINTERVENTION
44CITN-12CITNMISCELLANEOUSAIDS-related Malignancy and Condition;Gastrointestinal Cancer;Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Lung, Mediastinal, and Pleural Cancer;Lymphoma;Miscellaneous and Metastatic Cancer;Skin CancerActivePhase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant NeoplasmI39/63N/AINTERVENTION
45E4512ECOG-ACRINNCTNLung, Mediastinal, and Pleural CancerActiveA Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion ProteinIII105/168N/AINTERVENTION
46EA1131ECOG-ACRINNCTNBreast CancerActiveA Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neoadjuvant ChemotherapyIII336/562477SCREENING,INTERVENTION
47EA2142ECOG-ACRINNCTNEndocrine CancerActiveRandomized Phase II Study of Platinum and Etoposide Versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Tumors including Poorly Differentiated Neuroendocrine Carcinomas and Well-Differentiated Neuroendocrine NeoplasmsII50/80N/AINTERVENTION
48EA5162ECOG-ACRINNCTNLung, Mediastinal, and Pleural CancerTemporarily Closed to AccrualPhase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFRII21/20N/AINTERVENTION
49EAF151ECOG-ACRINNCTNCNS Cancer (Primary tumor)ActiveChange in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent GlioblastomaII65/165N/AINTERVENTION
50EAQ162CDECOG-ACRINCCDRGastrointestinal CancerActiveLongitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative IntentOtherN/AN/AOTHER